Search Results for "interferon beta-1a"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for interferon beta-1a. Results 1 to 3 of 3 total matches.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
Ozanimod: oh zan’ i mod Zeposia: zeh poe’ see ah
than interferon beta-1a in reducing relapse rates ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
interferon beta-1a (Plegridy), which is injected SC or
IM every 2 weeks, appears to be similar in efficacy ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Ponesimod (Ponvory) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
and ozanimod have been more effective
than interferon beta-1a in reducing relapse rates and
lesion ...
The FDA has approved ponesimod (Ponvory –
Janssen), a sphingosine 1-phosphate (S1P) receptor
modulator, for treatment of adults with relapsing forms
of multiple sclerosis (MS), including clinically isolated
syndrome (initial neurological episode), relapsing-remitting
disease, and active secondary progressive
MS (SPMS). Ponesimod is the fourth oral S1P receptor
modulator to be approved in the US for once-daily
treatment of relapsing forms of MS; ozanimod
(Zeposia) and siponimod (Mayzent) are also approved
for use in adults, and fingolimod (Gilenya) is indicated
for use in patients...